Cartesian Therapeutics Inc.
Frederick, MD
- UEI
- PXGLS86SY6B1
- CAGE
- 7NM42
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 7495 New Horizon Way, Frederick, MD 21703, USA
- Website
- cartesiantherapeutics.com
- Founded
- 2016
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Luminary Therapeutics, Inc. | Minneapolis, MN | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Creative Biotherapeutics LLC | Gurnee, IL | — |
| Aleutian Therapeutics, Inc. | Los Angeles, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Trethera Corp | Los Angeles, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Gigamune, Inc. | San Francisco, CA | — |
About the company
Cartesian Therapeutics Inc. is a biotechnology company focused on developing innovative cell and RNA-based therapies, with a particular emphasis on advancing treatment options for autoimmune disorders and neurological conditions. Registered in the System for Award Management (SAM.gov) since July 2016, the company operates as a for-profit corporate entity that specializes in developing cutting-edge therapeutic technologies, specifically RNA-engineered chimeric antigen receptor (CAR) T cell therapies. The company's approach centers on creating novel cell therapies that offer more targeted and potentially less toxic treatment alternatives compared to traditional medical interventions.
The company has secured multiple significant federal grant awards from prominent National Institutes of Health (NIH) agencies, including the National Institute of Neurological Disorders and Stroke (NINDS), the National Heart Lung and Blood Institute, and the National Institute of Allergy and Infectious Diseases (NIAID). These awards have supported the development of several innovative therapeutic approaches, such as Descartes-08, an RNA-based CAR T cell therapy targeting B cell maturation antigen (BCMA) for treating autoimmune disorders like systemic lupus erythematosus (SLE) and myasthenia gravis. Another notable project is Descartes-30, an allogeneic mesenchymal stem cell therapy designed to address acute respiratory distress syndrome (ARDS), including COVID-19-related complications. The federal grants, ranging from cooperative agreements to project grants, have provided funding between approximately $149,000 and $1.5 million to support clinical research, product manufacturing, and clinical trial development across various stages of therapeutic investigation.
Quick answers
Is Cartesian Therapeutics Inc. registered in SAM.gov?
Yes. Cartesian Therapeutics Inc.'s SAM.gov registration is active through February 25, 2027.
What is Cartesian Therapeutics Inc.'s most recent federal award?
Cartesian Therapeutics Inc.'s most recent federal grant award is Targeting bcma+ cells with RNA-engineered car t cells to treat lupus: a phase 2 clinical study - systemic lupus… (U44AI184200), from National Institute of Allergy and Infectious Diseases (NIH), on August 14, 2024.
On GovTribe
See Cartesian Therapeutics Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors